CL2021001202A1 - Polímeros oligonucleótidos que inhiben el transporte de antígeno s y métodos - Google Patents
Polímeros oligonucleótidos que inhiben el transporte de antígeno s y métodosInfo
- Publication number
- CL2021001202A1 CL2021001202A1 CL2021001202A CL2021001202A CL2021001202A1 CL 2021001202 A1 CL2021001202 A1 CL 2021001202A1 CL 2021001202 A CL2021001202 A CL 2021001202A CL 2021001202 A CL2021001202 A CL 2021001202A CL 2021001202 A1 CL2021001202 A1 CL 2021001202A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- stops
- antigen transport
- inhibit antigen
- polymers
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 229920000642 polymer Polymers 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
- 101710137302 Surface antigen S Proteins 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 230000032258 transport Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3527—Other alkyl chain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3535—Nitrogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862757632P | 2018-11-08 | 2018-11-08 | |
| US201962855323P | 2019-05-31 | 2019-05-31 | |
| US201962907845P | 2019-09-30 | 2019-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001202A1 true CL2021001202A1 (es) | 2021-12-17 |
Family
ID=70551410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001202A CL2021001202A1 (es) | 2018-11-08 | 2021-05-06 | Polímeros oligonucleótidos que inhiben el transporte de antígeno s y métodos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20200147124A1 (https=) |
| EP (1) | EP3853240A4 (https=) |
| JP (1) | JP2022512975A (https=) |
| KR (1) | KR20210090217A (https=) |
| CN (1) | CN113286803A (https=) |
| AU (1) | AU2019376079A1 (https=) |
| BR (1) | BR112021008539A2 (https=) |
| CA (1) | CA3117163A1 (https=) |
| CL (1) | CL2021001202A1 (https=) |
| CO (1) | CO2021005762A2 (https=) |
| IL (1) | IL282640A (https=) |
| MA (1) | MA53674A (https=) |
| MX (1) | MX2021005357A (https=) |
| PE (1) | PE20211783A1 (https=) |
| PH (1) | PH12021551007A1 (https=) |
| SG (1) | SG11202104636XA (https=) |
| TW (1) | TW202031267A (https=) |
| WO (1) | WO2020097342A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| US20200385713A1 (en) * | 2019-01-22 | 2020-12-10 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| AU2020260105A1 (en) | 2019-04-17 | 2021-11-04 | Aligos Therapeutics, Inc. | Bicyclic and tricyclic compounds |
| SG11202112741XA (en) | 2019-05-31 | 2021-12-30 | Aligos Therapeutics Inc | Modified gapmer oligonucleotides and methods of use |
| AU2020289537A1 (en) | 2019-06-06 | 2021-11-25 | Aligos Therapeutics, Inc. | Heterocyclic compounds |
| US20220281911A1 (en) * | 2019-08-19 | 2022-09-08 | Mina Therapeutics Limited | Oligonucleotide conjugate compositions and methods of use |
| IL291251B1 (en) * | 2019-09-10 | 2026-02-01 | Daiichi Sankyo Co Ltd | Oligonucleotide-galnac conjugate for targeted delivery to the liver and method for its production |
| US20210189392A1 (en) * | 2019-12-12 | 2021-06-24 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| PE20221578A1 (es) | 2020-03-06 | 2022-10-06 | Aligos Therapeutics Inc | Moleculas de acido nucleico interferente corto (sina, por sus siglas en ingles) modificadas y usos de estas |
| JP2023534557A (ja) * | 2020-07-23 | 2023-08-09 | エフ． ホフマン－ラ ロシュ アーゲー | Ｒｎａ結合タンパク質部位を標的とするオリゴヌクレオチド |
| AU2021318943A1 (en) * | 2020-07-27 | 2023-03-02 | Aligos Therapeutics, Inc. | HBV binding oligonucleotides and methods of use |
| EP4229062A4 (en) | 2020-10-15 | 2024-10-30 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| JP2023548031A (ja) | 2020-10-21 | 2023-11-15 | アリゴス セラピューティクス インコーポレイテッド | 二環式化合物 |
| WO2022109129A1 (en) * | 2020-11-20 | 2022-05-27 | Aligos Therapeutics, Inc. | Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting |
| EP4251625A4 (en) | 2020-11-24 | 2024-10-09 | Aligos Therapeutics, Inc. | Tricyclic compounds |
| TW202245809A (zh) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
| WO2022152869A1 (en) | 2021-01-15 | 2022-07-21 | Janssen Sciences Ireland Unlimited Company | Use of oligonucleotides for individuals with hepatic impairment |
| CA3204340A1 (en) * | 2021-01-30 | 2022-08-04 | Ahmad Ali MORTAZAVI | Conjugated oligonucleotide compounds, methods of making and uses thereof |
| JP2024504504A (ja) * | 2021-01-30 | 2024-01-31 | イー セラピューティクス パブリック リミテッド カンパニー | コンジュゲートオリゴヌクレオチド化合物、その作製方法及び使用 |
| WO2022162157A1 (en) * | 2021-01-30 | 2022-08-04 | E-Therapeutics Plc | Conjugated oligonucleotide compounds, methods of making and uses thereof |
| CN115850358B (zh) * | 2021-03-08 | 2026-04-24 | 南京吉迈生物技术有限公司 | GalNAc簇亚磷酰胺和靶向治疗性核苷 |
| EP4349986A4 (en) * | 2021-05-25 | 2025-11-19 | Univ Nat Corp Tokyo Medical & Dental | HETERONUCLEIC ACID WITH A CONTENT OF ?????? OR ???? |
| US11957683B2 (en) | 2021-06-18 | 2024-04-16 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| JP2024527380A (ja) | 2021-07-09 | 2024-07-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド | 腎機能障害を有する個体へのオリゴヌクレオチドの使用 |
| US20250243491A1 (en) | 2021-09-01 | 2025-07-31 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
| EP4399217A2 (en) | 2021-09-08 | 2024-07-17 | Aligos Therapeutics, Inc. | Modified short interfering nucleic acid (sina) molecules and uses thereof |
| CN118234862A (zh) | 2021-09-08 | 2024-06-21 | 阿利戈斯治疗公司 | 经修饰的短干扰核酸分子(siNA)及其用途 |
| CN114230624A (zh) * | 2021-12-22 | 2022-03-25 | 上海兆维科技发展有限公司 | 一种核苷二聚体亚膦酰胺的合成方法 |
| KR20240158340A (ko) | 2022-03-17 | 2024-11-04 | 알리고스 테라퓨틱스 인코포레이티드 | 변형 갭머 올리고머 및 이의 사용 방법 |
| EP4511374A4 (en) | 2022-04-20 | 2026-04-08 | Aligos Therapeutics Inc | BICYCLE COMPOUNDS |
| WO2023222858A1 (en) * | 2022-05-18 | 2023-11-23 | F. Hoffmann-La Roche Ag | Improved oligonucleotides targeting rna binding protein sites |
| WO2024182446A2 (en) | 2023-02-28 | 2024-09-06 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
| US20240352464A1 (en) | 2023-03-07 | 2024-10-24 | Aligos Therapeutics, Inc. | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof |
| CN121175419A (zh) * | 2023-04-14 | 2025-12-19 | 苏州炫景生物科技有限公司 | 抑制c3基因表达的化合物、药物组合物及其用途 |
| WO2025143262A1 (ja) * | 2023-12-28 | 2025-07-03 | 日産化学株式会社 | カルバモイルエチル修飾を含有する二本鎖ｒｎａ |
| CN117534717A (zh) * | 2024-01-09 | 2024-02-09 | 凯莱英生命科学技术(天津)有限公司 | 5′-(e)-乙烯基磷酸酯的合成方法 |
| US20250368996A1 (en) | 2024-05-14 | 2025-12-04 | Aligos Therapeutics, Inc. | Modified antisense oligonucleotides for treating hepatitis b virus |
| US20250382618A1 (en) * | 2024-06-14 | 2025-12-18 | Aligos Therapeutics, Inc. | Methods and compositions for inhibiting virus |
| CN119569802B (zh) * | 2025-02-06 | 2025-06-13 | 北京安龙生物医药有限公司 | 修饰寡核苷酸的化合物、其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101084232A (zh) * | 2004-10-19 | 2007-12-05 | 里普利科股份有限公司 | 抗病毒寡核苷酸 |
| JPWO2006043521A1 (ja) * | 2004-10-19 | 2008-05-22 | 日本新薬株式会社 | ホスホロチオエート結合を有する光学活性なオリゴ核酸化合物 |
| WO2007090071A2 (en) * | 2006-01-27 | 2007-08-09 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| BR112013003875B1 (pt) * | 2010-08-20 | 2021-10-05 | Replicor Inc | Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos |
| SMT202100319T1 (it) * | 2012-05-18 | 2021-09-14 | Replicor Inc | Composizioni e metodi del complesso oligonucleotide chelato polipeptidico |
| CN106659730A (zh) * | 2014-07-10 | 2017-05-10 | 里普利科股份有限公司 | 治疗b型肝炎和d型肝炎病毒感染的方法 |
| KR102533038B1 (ko) * | 2016-09-14 | 2023-05-17 | 얀센 바이오파마, 인크. | 변형된 올리고뉴클레오티드 및 사용 방법 |
-
2019
- 2019-11-07 PE PE2021000674A patent/PE20211783A1/es unknown
- 2019-11-07 CA CA3117163A patent/CA3117163A1/en active Pending
- 2019-11-07 AU AU2019376079A patent/AU2019376079A1/en not_active Abandoned
- 2019-11-07 WO PCT/US2019/060283 patent/WO2020097342A1/en not_active Ceased
- 2019-11-07 KR KR1020217017323A patent/KR20210090217A/ko not_active Withdrawn
- 2019-11-07 CN CN201980088039.4A patent/CN113286803A/zh active Pending
- 2019-11-07 EP EP19880948.5A patent/EP3853240A4/en not_active Withdrawn
- 2019-11-07 JP JP2021525122A patent/JP2022512975A/ja active Pending
- 2019-11-07 SG SG11202104636XA patent/SG11202104636XA/en unknown
- 2019-11-07 MX MX2021005357A patent/MX2021005357A/es unknown
- 2019-11-07 MA MA053674A patent/MA53674A/fr unknown
- 2019-11-07 BR BR112021008539-4A patent/BR112021008539A2/pt not_active IP Right Cessation
- 2019-11-07 US US16/676,929 patent/US20200147124A1/en not_active Abandoned
- 2019-11-08 TW TW108140604A patent/TW202031267A/zh unknown
-
2021
- 2021-04-26 IL IL282640A patent/IL282640A/en unknown
- 2021-04-30 CO CONC2021/0005762A patent/CO2021005762A2/es unknown
- 2021-05-03 PH PH12021551007A patent/PH12021551007A1/en unknown
- 2021-05-06 CL CL2021001202A patent/CL2021001202A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021551007A1 (en) | 2021-10-04 |
| AU2019376079A1 (en) | 2021-05-27 |
| TW202031267A (zh) | 2020-09-01 |
| US20200147124A1 (en) | 2020-05-14 |
| CO2021005762A2 (es) | 2021-07-30 |
| BR112021008539A2 (pt) | 2021-08-03 |
| SG11202104636XA (en) | 2021-06-29 |
| EP3853240A4 (en) | 2022-11-30 |
| WO2020097342A1 (en) | 2020-05-14 |
| CN113286803A (zh) | 2021-08-20 |
| JP2022512975A (ja) | 2022-02-07 |
| CA3117163A1 (en) | 2020-05-14 |
| IL282640A (en) | 2021-06-30 |
| MX2021005357A (es) | 2021-06-30 |
| EP3853240A1 (en) | 2021-07-28 |
| PE20211783A1 (es) | 2021-09-08 |
| MA53674A (fr) | 2021-07-28 |
| KR20210090217A (ko) | 2021-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001202A1 (es) | Polímeros oligonucleótidos que inhiben el transporte de antígeno s y métodos | |
| MX2017008500A (es) | Supresión del gen de la huntingtina inducida por la arni. | |
| CU23938B1 (es) | Moléculas de unión humanas capaces de neutralizar el virus de la influenza h3n2 | |
| MX2018004978A (es) | Oligonucleotidos para inducir la expresion paterna de la ligasa de la proteina ubiquitina e3a (ube3a). | |
| BR112016004091A2 (pt) | métodos e composições para tratamento guiado por rna de infecção por hiv | |
| MX2019008380A (es) | Composiciones de arni contra el componente c5 del complemento y metodos para su uso. | |
| UA117098C2 (uk) | Сполука, що містить модифікований олігонуклеотид | |
| CL2020001344A1 (es) | Tratamiento antisentido del síndrome de angelman. | |
| MX350282B (es) | Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas. | |
| UY32634A (es) | Respuesta inmunitaria reforzada en especies aviares | |
| MX381042B (es) | Uso de un complejo quelato y un anàlogo de neucleòsido o neucleòtido para tratar infecciones de virus de la hepatitis b y hepatitis d. | |
| MX2020012652A (es) | Oligonucleotido bicatenario especifico del gen de anfirregulina y composicion para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo. | |
| EA201791471A1 (ru) | Способы применения антисмысловых олигонуклеотидов smad7 | |
| MX2016009747A (es) | Vacunas contra el reovirus aviar. | |
| EA202190964A1 (ru) | Олигонуклеотидные полимеры и способы для ингибирования транспорта s-антигена | |
| AR117009A1 (es) | Polímeros oligonucleótidos que inhiben el transporte de antígenos y métodos | |
| RU2014144094A (ru) | Способы воздействия на экспрессию гена CREBBP | |
| RU2014142757A (ru) | Способ воздействия на экспрессию гена TCF | |
| RU2014144093A (ru) | Способы воздействия на экспрессию гена CRE | |
| RU2014142756A (ru) | Способы воздействия на экспрессию гена D4DR | |
| RU2014144701A (ru) | Способы воздействия на экспрессию гена TER1 | |
| RU2014142755A (ru) | Способы воздействия на экспрессию гена CYP17 | |
| RU2014143385A (ru) | Способы воздействия на экспрессию гена TP53 | |
| AR127877A2 (es) | COMPOSICIONES DE ARNi DEL COMPONENTE DEL COMPLEMENTO C5 Y MÉTODOS PARA SU USO | |
| MX2020013270A (es) | Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato. |